v3.26.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Apr. 30, 2026
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The following tables reflect segment results under our management reporting system after excluding certain unallocated costs as noted in the reconciliations below:
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Three Months Ended April 30, 2026:
Net Revenue$732 $759 $344 $1,835 
Segment Expenses (1)
Cost of products and services337 338 152 
Research and development64 28 24 
Selling, general and administrative170 151 88 
Reportable segment income from operations$161 $242 $80 $483 
Three Months Ended April 30, 2025:
Net Revenue$654 $713 $301 $1,668 
Segment Expenses (1)
Cost of products and services309 317 140 
Research and development59 27 23 
Selling, general and administrative157 138 79 
Reportable segment income from operations$129 $231 $59 $419 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Three Months Ended April 30,
Three Months Ended April 30,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$11 $$26 $24 
Agilent CrossLab$12 $11 $14 $14 
Applied Markets$$$$
Life Sciences and Diagnostics MarketsAgilent CrossLabApplied MarketsTotal
(in millions)
Six Months Ended April 30, 2026:
Net Revenue$1,411 $1,517 $705 $3,633 
Segment Expenses (1)
Cost of products and services673 678 309 
Research and development129 56 48 
Selling, general and administrative339 301 175 
Reportable segment income from operations$270 $482 $173 $925 
Six Months Ended April 30, 2025:
Net Revenue$1,301 $1,409 $639 $3,349 
Segment Expenses (1)
Cost of products and services614 623 290 
Research and development122 53 46 
Selling, general and administrative319 281 160 
Reportable segment income from operations$246 $452 $143 $841 
(1) Share-based compensation expense and depreciation expense included in segment expenses are shown below:
Share-Based Compensation ExpenseDepreciation Expense
Six Months Ended April 30,
Six Months Ended April 30,
2026202520262025
(in millions)(in millions)
Life Sciences and Diagnostics Markets$25 $24 $52 $47 
Agilent CrossLab$28 $27 $28 $28 
Applied Markets$13 $13 $13 $12 
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments' income from operations to Agilent’s total enterprise income before taxes: 
Three Months EndedSix Months Ended
 April 30,April 30,
 2026202520262025
 (in millions)
Total reportable segment income from operations$483 $419 $925 $841 
Unallocated costs:
Amortization of intangible assets related to business combinations(19)(27)(38)(55)
Acquisition and integration costs(12)(3)(15)(12)
Transformational initiatives(39)(24)(58)(30)
Restructuring and other related costs(8)(56)(28)(57)
Other(6)(9)(34)(11)
Total unallocated costs(84)(119)(173)(165)
Income from operations399 300 752 676 
Interest income13 14 28 29 
Interest expense(25)(29)(50)(57)
Other income (expense), net21 (25)42 (21)
Income before taxes, as reported$408 $260 $772 $627